The Adventist Health System has named Terry Shaw as the organization’s new president and chief executive officer. Shaw will immediately assume leadership responsibilities for the faith-based health care system.
The system includes 46 hospital campuses in 10 states, as well as a host of urgent care centers, home health and hospice agencies, physician practices and skilled nursing facilities.
Shaw’s career with Adventist Health System spans more than 30 years. Immediately prior to being named president/CEO, he served as executive vice president, chief financial officer and chief operations officer, where his grasp of healthcare finance, IT and overall operations enabled him to help define the organization’s vision and direction.
He began his career with AHS as a business intern in 1982. He was appointed director at Florida Hospital in 1985, assistant vice president in 1990, vice president in 1992 and senior vice president in 1996. In 2000, Shaw became senior vice president and chief financial officer for AHS, a role he held until 2010 when he gained COO responsibilities.
Shaw received bachelor’s degrees in accounting and computer science from Southern Adventist University, and a master’s degree in administration from the University of Central Florida.
He currently serves as vice chairman of the Premier board of directors and is a member of the Hospital Financial Management Association, American College of Healthcare Executives and State of Texas Board of Certified Accountants. As a silver level Leadership Society contributor to the United Way, Shaw supports and donates to the nonprofit organization, and is also active with several other professional and service organizations.
He and his wife, Paula, reside in Orlando, Florida and have two adult sons. Don Jernigan, who officially retired as Adventist Health System’s president/CEO on Dec. 8 after leading the organization for more than a decade, will transition to a faculty role at the Adventist Health System Leadership Institute.
By Jeff Lagasse
Source: Healthcare Finance
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.
